The promise of stem cells, along with the controversy surrounding it, has made the industry a hot-button issue for many. Despite that promise, we have yet to see huge applicable benefits to humans. That could be changing. Cloning embryonic stem cells could mark a dramatic shift and improve on what is already a nascent process.

In this video, health-care analyst David Williamson discusses this breakthrough and what it means for investors interested in stem cell stocks.